AIVITA Biomedical CEO Hans Keirstead, Ph.D. to Speak at Stem Cell Cures Consortium Conference
Dr. Keirstead will speak about the current regenerative medicine landscape, Company’s own clinical progress and promising avenues of stem cell research
IRVINE, Calif. – June 7, 2017 – AIVITA Biomedical today announced that Chief Executive Officer Hans Keirstead, Ph.D. will be speaking at the upcoming Stem Cell Cures Consortium Conference. The conference, taking place June 8th at the Gladstone Institutes in San Francisco, will bring together academic and industry leaders in the field of regenerative medicine to discuss ongoing research and explore new ways of using stem cells to treat various neurological diseases and disorders.
“I’m honored to have been invited to take part in this conference and look forward to having collaborative discussions with peers who share my interest in finding cures,” said Dr. Keirstead. “This is a great opportunity for us to provide updates and evaluate progress towards addressing life-altering injuries such as acute spinal cord injury.”
The Stem Cell Cures Consortium Conference is organized by Roman Reed, a patient advocate for spinal cord injury and Executive Director of Stanford University School of Medicine’s partnership for Spinal Cord Injury Repair. As head of the Roman Reed Foundation, a 501(c)(3) charitable organization dedicated to finding cures for neurological disorders, Reed advocates for a unified approach to the field of regenerative medicine. The Stem Cell Cures Consortium represents hist latest effort to bring top minds together to develop solutions for patients suffering from various neurological disorders.
Showing its support for the cause, AIVITA Biomedical is a Bronze Sponsor of the Stem Cell Cures Consortium Conference.
About AIVITA Biomedical
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial line of skin care products and therapeutic pipeline. All proceeds from the sale of AIVITA’s skin care products directly support its clinical development program, including a platform immunotherapy for the treatment of advanced cancers.